NodThera Announces Appointment of Greg Chow as Chief Financial and Business Officer
2024年8月1日 - 8:00PM
NodThera Announces Appointment of Greg
Chow as Chief Financial and Business Officer
- Greg brings over 25 years of public
and private company leadership experience
Philadelphia, PA, August 1,
2024 - NodThera, a leading clinical-stage biotech
delivering a paradigm shift in the treatment of chronic
inflammatory diseases through selective modulation of the NLRP3
inflammasome, today announces the appointment of Greg Chow as Chief
Financial and Business Officer (CFBO), effective immediately.
Greg is an experienced executive with over 25
years of corporate finance, capital markets, investment banking,
financial accounting, drug development operations, and business
development experience. Over the course of his career, he has led
major financing rounds for both public and private companies, as
well as supported operations and administrative functions.
Greg joins NodThera from Freenome Holdings,
where he served as Chief Financial Officer (CFO) and helped
successfully execute the company’s recent $254 million Series F
financing round. Prior to Freenome, Greg was CFO at Frontier
Medicines, where he helped lead its Series B and C fundraising
rounds and headed up Alliance Management for its global, multi-year
collaboration with AbbVie. His leadership across Frontier’s
business operations was instrumental in helping the company
transition from a discovery-stage to clinical-stage organization.
He gained significant public company experience as Executive Vice
President and CFO at Aptose Biosciences (Nasdaq: APTO), overseeing
the company’s dual listing on the Nasdaq and Toronto stock
exchanges in addition to successfully raising over $225 million and
attracting multiple new shareholders.
Prior to his time as an industry executive, Greg
spent 14 years in investment banking as Managing Director and
Director of Private Placements at Wedbush Securities and in senior
roles at RBC Capital Markets and Wells Fargo Securities. Greg holds
an MBA in Finance from the Wharton School at the University of
Pennsylvania and a BA in Business Economics, from the University of
California, Santa Barbara. He is a Certified Public Accountant
(inactive) in the state of California.
Daniel Swisher, Chief Executive Officer
of NodThera, said: “Greg’s financial experience and
extensive track record of long-term value creation for both private
and public biotechs will be invaluable as NodThera continues to
execute its strategy and evolves into a mature, high-value,
clinical-stage company. I look forward to working closely with him
as part of our executive team. Greg will be a key strategic partner
as we continue to unlock the broad potential and maximum value of
our highly differentiated brain-penetrant NLRP3 inflammasome
inhibitors in the treatment of chronic inflammatory diseases. On
behalf of the whole team, I would like to wish him a very warm
welcome to NodThera.”
Greg Chow, Chief Financial and Business
Officer of NodThera, added: “I am incredibly excited to
join NodThera at such a pivotal time in its development. The
potential to modulate inflammation for the treatment of chronic
diseases presents a significant opportunity to impact patients’
lives in a meaningful way. I look forward to being immersed in one
of the most exciting and rapidly evolving therapeutic categories in
biotech today. With a highly accomplished team, positive
progression of lead candidate NT-0796 and upcoming Phase II studies
in obesity, cardiovascular and Parkinson’s disease, NodThera is
well positioned in its current trajectory with some important
inflection points on the near-term horizon. I am eager to bring my
capital markets, operations, and business development experience to
NodThera and look forward to partnering with Dan, the Board of
Directors and the wider team.”
For more information about NodThera
please contact:
NodTheraTel: +44 (0) 1223
608130Email: info@nodthera.com
ICR Consilium Amber Fennell, David Daley,
Sukaina Virji Tel: +44 (0)20 3709 5700Email:
nodthera@consilium-comms.com
About NodTheraNodThera is a
leading clinical-stage biotech developing brain-penetrant NLRP3
inflammasome inhibitors to treat chronic inflammatory diseases. Led
by an experienced management team, NodThera is combining a deep
understanding of NLRP3 inhibition, pharmaceutical neuroscience
expertise and precision chemistry. Its two lead clinical candidates
are oral, small molecule NLRP3 inflammasome inhibitors, which have
demonstrated differentiated, potentially best-in-class clinical
profiles with significant anti-inflammatory effects and high brain
penetration, offering distinct opportunities to treat multiple
indications. The Company is backed by top-tier investors including
5AM Ventures, Blue Owl Capital, Epidarex Capital, F-Prime Capital,
Novo Holdings, Sanofi Ventures and Sofinnova Partners. NodThera is
headquartered in Philadelphia, Pennsylvania, with additional
operations in Cambridge, UK and Seattle, WA. Learn more at
www.nodthera.com or follow the Company on LinkedIn.